Hemochromatosis: all 67 studies

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary HemochromatosisRecruitingNCT07371793Phase 1/2
• "Iron Overload and Endocrinological Diseases"RecruitingNCT06137079
• Leflunomide for Idiopathic Pulmonary Hemosiderosis in ChildrenRecruitingNCT05937191Phase 1/2
• PTG-300 in Subjects With Hereditary HemochromatosisCompletedNCT04202965Phase 2Results posted
• A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary HemochromatosisCompletedNCT03395704Phase 2Results posted
• Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional HemosiderosisCompletedNCT03372083Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)TerminatedNCT03203850Phase 2Results posted
• Clinical Importance of Treating Iron Overload in Sickle Cell DiseaseTerminatedNCT00981370Phase 3Results posted
• Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to FoodCompletedNCT00845871Phase 4Results posted
• Pilot Study for Patients With Poor Response to DeferasiroxCompletedNCT00749515Phase 4Results posted
• Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional HemosiderosisCompletedNCT00631163Phase 2Results posted
• Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron OverloadCompletedNCT00600938Phase 2Results posted
• Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary HemochromatosisCompletedNCT00395629Phase 1/2Results posted
• Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia PatientsCompletedNCT00303329Phase 2Results posted
• Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)CompletedNCT00171301Phase 4Results posted
• Stroke With Transfusions Changing to HydroxyureaTerminatedNCT00122980Phase 3Results posted
• Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary HemochromatosisActive, not recruitingNCT07332091Phase 2
• Analysis of the Effect of Iron Supplements on Iron Deficiency Anemia in PregnancyStatus unknownNCT05804071Phase 4
• Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.Status unknownNCT05742035Not applicable
• Iron Deposits in the Pancreas by MRI Method of Dialysis Patients With Hemosiderosis Iatrogenic (ERDFP)Status unknownNCT05593068
• A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient VolunteersTerminatedNCT05238207Phase 1
• Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE HaemochromatosisActive, not recruitingNCT04779593Not applicable
• MRI QSM Imaging for Iron OverloadCompletedNCT04631718
• The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric PatientsTerminatedNCT04284371
• Haemochromatosis and PeriodontitisCompletedNCT04006249Not applicable
• Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol SupplementCompletedNCT03990181Not applicable
• Repeatability and Reproducibility of Multiparametric MRICompletedNCT03743272
• Study of the Cellular Diffusion of Tacrolimus Across the Membrane of Mononuclear CellsCompletedNCT03654794
• Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.CompletedNCT03453918Not applicable
• Transferrin Saturation and Asthenia in HemochromatosisCompletedNCT03356548
• Respiratory Variations For Assessing Blood WithdrawalCompletedNCT03066414
• Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary HemosiderosisStatus unknownNCT02985346Early Phase 1
• Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial HemosiderosisWithdrawnNCT02664571Not applicable
• Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II StudyTerminatedNCT02263638Phase 2
• Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary HaemochromatosisCompletedNCT02099214Not applicable
• Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron ContentCompletedNCT02025543
• Implications for Quality of Life and Quality of Care in Patients With Hereditary HaemochromatosisWithdrawnNCT01991925
• Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.CompletedNCT01949467Phase 2
• Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeWithdrawnNCT01892644Phase 2
• Impact of Bloodletting on Iron Metabolism in Type 1 HemochromatosisCompletedNCT01810965Not applicable
• HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 HemochromatosisCompletedNCT01784939
• Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?CompletedNCT01631708Not applicable
• Pharmacogenetic Study in Patients Received Iron Chelating AgentCompletedNCT01623895
• Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary StudyCompletedNCT01556360
• Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary HemochromatosisStatus unknownNCT01524757Not applicable
• Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron OverloadStatus unknownNCT01511848Phase 2/3
• Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) PatientsStatus unknownNCT01398644Phase 3
• Observation of Patients With Transfusional Hemosiderosis Treatment With DeferasiroxCompletedNCT01394029
• Oral Nifedipine to Treat Iron OverloadCompletedNCT00712738Phase 1
• Evaluation of a New MR Pulse Sequence to Quantify Liver Iron ConcentrationCompletedNCT00587535
• Erythrocyte Apheresis Versus Phlebotomy in HemochromatosisStatus unknownNCT00509652Not applicable
• Safety, Tolerability, and Efficacy of Deferasirox in MDSCompletedNCT00469560Phase 3
• Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. ErythrocytoapheresisCompletedNCT00440986Phase 2/3
• Study With Deferiprone and/or Desferrioxamine in Iron Overloaded PatientsCompletedNCT00350662Phase 3
• Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent PatientsCompletedNCT00349453Phase 2
• Haemochromatosis:Phlebotomy Versus Erythrocytapheresis TherapyCompletedNCT00202436Phase 3
• Research Network for Neonatal Diseases Induced by Tissular Fetomaternal AlloimmunizationCompletedNCT00199628
• A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisCompletedNCT00171171Phase 3
• Efficacy Study in Removing Excess Iron From the HeartCompletedNCT00105495Phase 4
• Cardiac Function in Patients With Hereditary HemochromatosisCompletedNCT00068159
• Treatment of HemochromatosisActive, not recruitingNCT00007150Phase 2
• Hemochromatosis--Genetic Prevalence and PenetranceCompletedNCT00006312
• Statistical Basis for Hemochromatosis ScreeningCompletedNCT00005559
• Hemochromatosis and Iron Overload Screening Study (HEIRS)CompletedNCT00005541
• Iron Overload in African AmericansCompletedNCT00001455
• Deferoxamine for the Treatment of HemochromatosisCompletedNCT00001203
• Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional HemochromatosisCompletedNCT00000595Phase 2

← Hemochromatosis overview